<PAGE> 1
OMB APPROVAL
---------------------------
OMB Number: 3235-0145
---------------------------
Expires: December 31, 1997
Estimated average burden
hours per response....14.90
---------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. _________)*
SIBIA Neurosciences, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
825 732 10 0
- --------------------------------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 7 pages
<PAGE> 2
CUSIP NO. 825 732 10 0 13G PAGE 2 OF 7 PAGES
- --------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Novartis AG
- --------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
2 (b) / /
- --------------------------------------------------------------------------------
SEC USE ONLY
3
- --------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
Switzerland
- --------------------------------------------------------------------------------
NUMBER OF SOLE VOTING POWER
SHARES 5
BENEFICIALLY Novartis AG disclaims beneficial ownership
OWNED BY of 1,035,324 shares of Common Stock of SIBIA
EACH Neurosciences, Inc. currently owned by Novartis
REPORTING Produkte AG, a wholly-owned subsidiary of Novartis
PERSON AG.
WITH --------------------------------------------------------
SHARED VOTING POWER
6 0
--------------------------------------------------------
SOLE DISPOSITIVE POWER
7
Novartis AG disclaims beneficial ownership
of 1,035,324 shares of Common Stock of SIBIA
Neurosciences, Inc. currently owned by Novartis
Produkte AG, a wholly-owned subsidiary of Novartis
AG.
--------------------------------------------------------
SHARED DISPOSITIVE POWER
8 0
- --------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
9 PERSON
Novartis AG disclaims beneficial ownership of 1,035,324
shares of Common Stock of SIBIA Neurosciences, Inc. currently
owned by Novartis Produkte AG, a wholly-owned subsidiary of
Novartis AG.
- --------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
10 CERTAIN SHARES*
- --------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
Novartis AG disclaims beneficial ownership of 1,035,324
shares of Common Stock of SIBIA Neurosciences, Inc. which
represents 11.3% of that class of Common Stock.
- --------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12 CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE> 3
CUSIP NO. 825 732 10 0 13G PAGE 3 OF 7 PAGES
- --------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Novartis Produkte AG
- --------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
2 (b) / /
- --------------------------------------------------------------------------------
SEC USE ONLY
3
- --------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
Switzerland
- --------------------------------------------------------------------------------
NUMBER OF SOLE VOTING POWER
SHARES 5 1,035,324
BENEFICIALLY --------------------------------------------------------
OWNED BY SHARED VOTING POWER
EACH 6 0
REPORTING --------------------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 1,035,324
--------------------------------------------------------
SHARED DISPOSITIVE POWER
8 0
- --------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
9 PERSON
Novartis Produkte AG which beneficially owns 1,035,324 shares of Common Stock
of SLBLA Neurosciences Inc., is a wholly-owned subsidiary of Novartis AG.
Novartis AG disclaims beneficial ownership of said 1,035,324 shares of
Common Stock of SIBIA Neurosciences, Inc.
- --------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
10 CERTAIN SHARES*
- --------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
11.3%
- --------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12 CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE> 4
ITEM 1.
(a) Name of Issuer: SIBIA Neurosciences, Inc.
(b) Address of Issuer's Principal Executive Offices:
505 Coast Boulevard South, Suite 300
La Jolla, CA 92037
ITEM 2.
(a) Name of Person Filing: Novartis AG and Novartis Produkte AG
(b) Address of Principal Business Office or, if none, Residence:
The principal address of Novartis AG and Novartis Produkte AG is
CH-4002 Basel, Switzerland.
(c) Citizenship:
Novartis AG and Novartis Produkte AG are each Swiss Corporations.
(d) Title of Class of Securities: Common Stock, $.001 par value
(e) CUSIP Number: 825 732 10 0
ITEM 3. NOT APPLICABLE.
ITEM 4. OWNERSHIP.
(a) Amount Beneficially Owned:
Novartis AG disclaims beneficial ownership of 1,035,324 shares of
Common Stock of SIBIA Neurosciences, Inc. currently owned by Novartis
Produkte AG, a wholly-owned subsidiary of Novartis AG.
(b) Percent of Class: 11.3%
(c) Number of shares as to which such person has:
<TABLE>
<S> <C>
(i) sole power to vote or to direct the vote: 1,035,324
(ii) shared power to vote or to direct the vote: Not Applicable
(iii) sole power to dispose or to direct the disposition of: 1,035,324
(iv) shared power to dispose or to direct the disposition of: Not Applicable
</TABLE>
Page 4 of 7 pages
<PAGE> 5
Novartis Produkte AG, which beneficially owns 1,035,324 shares of
Common Stock of SIBIA Neurosciences, Inc., is a wholly-owned subsidiary
of Novartis AG. Novartis AG disclaims beneficial ownership of said
1,035,324 shares of Common Stock of SIBIA Neurosciences, Inc.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not Applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary
course of business and were not acquired for the purpose of and do not
have the effect of changing or influencing the control of the issuer of
such securities and were not acquired in connection with or as a
participant in any transaction having such purposes or effect.
Page 5 of 7 pages
<PAGE> 6
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: February 14, 1997
NOVARTIS AG
By: /s/ Ingrid Duplain
--------------------------------
Name: Ingrid Duplain
Title: Authorized Signatory
NOVARTIS PRODUKTE AG
By: /s/ Pierre Douaze
--------------------------------
Name: Pierre Douaze
Title: Authorized Signatory
Page 6 of 7 pages
<PAGE> 1
AGREEMENT
JOINT FILING OF SCHEDULE 13G
The undersigned hereby agrees to file jointly the Statement on
Schedule 13G (the "Statement") relating to the Common Stock, $.001 par value per
share, of SIBIA Neurosciences, Inc., and any further amendments thereto which
may be deemed necessary pursuant to Regulation 13D or G promulgated under
Section 13 of the Securities Exchange Act of 1934, as amended.
It is understood and agreed that a copy of this Agreement
shall be attached as an exhibit to the Statement, filed on behalf of each of the
parties hereto.
This Agreement may be executed in multiple counterparts, each
of which shall constitute an original, one and the same instrument.
IN WITNESS WHEREOF, each of the undersigned has executed this
Agreement as of the 14 day of February, 1997.
NOVARTIS AG
By: /s/ Ingrid Duplain
--------------------------------
Name: Ingrid Duplain
Title: Authorized Signatory
NOVARTIS PRODUKTE AG
By: /s/ Pierre Douaze
--------------------------------
Name: Pierre Douaze
Title: Authorized Signatory
Page 7 of 7 pages
